SCHEMBL2814913

SCHEMBL2814913

O=C(Cl)Nc1ccccc1Cc1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.66
ALDH1A1 P00352 4/20 0.51
HPGD P15428 2/20 0.50
MAOB P27338 1/20 0.49
LMNA P02545 3/20 0.49
HTT P42858 2/20 0.49
PKM P14618 1/20 0.48
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
POLB P06746 1/20 0.47
MAPT P10636 1/20 0.47
RECQL P46063 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MCOLN3 Q8TDD5 1/20 0.47
KDM4E B2RXH2 1/20 0.44
IDH1 O75874 1/20 0.44
NPY5R Q15761 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11412191 0.88 L3MBTL1 (0.53) L3MBTL1ALDH1A1HPGDMAOBLMNA
SCHEMBL4172605 0.85 L3MBTL1 (0.70) L3MBTL1ALDH1A1HPGDMAOBLMNA
Hydrochloric Acid SCHEMBL11164652 0.84 L3MBTL1 (0.68) L3MBTL1ALDH1A1HPGDMAOBLMNA
SCHEMBL27547012 0.84 L3MBTL1 (0.68) L3MBTL1ALDH1A1HPGDMAOBLMNA
SCHEMBL2419022 0.84 L3MBTL1 (0.68) L3MBTL1ALDH1A1HPGDMAOBLMNA
SCHEMBL22966593 0.83 L3MBTL1 (0.62) L3MBTL1ALDH1A1HPGDMAOBLMNA
SCHEMBL9544162 0.82 L3MBTL1 (0.66) L3MBTL1ALDH1A1HPGDMAOBLMNA
SCHEMBL7522410 0.82 L3MBTL1 (0.71) L3MBTL1ALDH1A1HPGDMAOBLMNA
SCHEMBL21504754 0.81 L3MBTL1 (0.73) L3MBTL1ALDH1A1HPGDMAOBLMNA
SCHEMBL10690887 0.81 L3MBTL1 (0.64) L3MBTL1ALDH1A1HPGDMAOBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100249420-A9 Process for preparing quinuclidinium carbamate derivatives LABORATORIOS ALMIRALL S.A. (ES) 2010-09-30 US disclosed
US-7776879-B2 Quinuclidine carbamate derivatives and their use as M3 antagonists ALMIRALL, S.A. (ES) 2010-08-17 US disclosed
US-20090198064-A1 Process for preparing quinuclidinium carbamate derivatives LABORATORIOS ALMIRALL S.A. (ES) 2009-08-06 US disclosed
EP-1781651-B1 PROCESS FOR PREPARING QUINUCLIDINIUM CARBAMATE DERIVATIVES ALMIRALL LAB (ES) 2009-03-11 EP disclosed
US-20090054480-A1 NOVEL QUINUCLIDINE CARBAMATE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME LABORATORIOS ALMIRALL S.A. 2009-02-26 US disclosed
US-20090005412-A1 NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME LABORATORIOS ALMIRALL S.A. 2009-01-01 US disclosed
US-7435742-B2 Quinuclidine derivatives and pharmaceutical compositions containing the same LABORATORIOS ALMIRALL S.A. (ES) 2008-10-14 US disclosed
US-20080021060-A1 Quinuclidine carbamate derivatives and their use as M3 antagonists ALMIRALL PRODESFARMA AG 2008-01-24 US disclosed
US-7312231-B2 Quinuclidine carbamate derivatives and their use as M3 antagonists ALMIRALL PRODESFARMA AG (CH) 2007-12-25 US disclosed
EP-1781651-A1 PROCESS FOR PREPARING QUINUCLIDINIUM CARBAMATE DERIVATIVES Laboratorios Almirall, S.A. (ES) 2007-05-09 EP disclosed
EP-1345937-B1 QUINUCLIDINE CARBAMATE DERIVATIVES AND THEIR USE AS M3 ANTAGONISTS ALMIRALL PRODESFARMA AG (CH) 2005-09-28 EP disclosed
EP-1515968-A2 QUINUCLIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME Almirall Prodesfarma AG (CH) 2005-03-23 EP disclosed
US-20040266816-A1 Quinuclidine carbamate derivatives and their use as M3 antagonists ALMIRALL, S.A. (ES) 2004-12-30 US disclosed
US-20040242629-A1 Quinuclidine carbamate derivatives and their use as M3 antagonists LABORATORIOS ALMIRALL S.A. (ES) 2004-12-02 US disclosed
WO-2004000840-A2 QUINUCLIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME ALMIRALL PRODESFARMA AG (CH) 2003-12-31 WO disclosed
EP-1345937-A1 QUINUCLIDINE CARBAMATE DERIVATIVES AND THEIR USE AS M3 ANTAGONISTS Almirall Prodesfarma, S.A. (ES) 2003-09-24 EP disclosed
WO-2002051841-A1 QUINUCLIDINE CARBAMATE DERIVATIVES AND THEIR USE AS M3 ANTAGONISTS ALMIRALL PRODESFARMA AG (CH) 2002-07-04 WO disclosed
US-4388246-A THERMAL SPLITTING OF CARBAMATES BAYER AKTIENGESELLSCHAFT (DE) 1983-06-14 US disclosed
US-4088766-A PRODUCTION OF PROSTAGLANDINS IN MAMMALS THE UPJOHN COMPANY (US) 1978-05-09 US disclosed
US-4001256-A PROSTAGLANDIN PRODUCTION IN MAMMALS THE UPJOHN COMPANY (US) 1977-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090005412-A1 NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME CHRM3, CHRM2, CHRM1 L3MBTL1 4595/4885ALDH1A1 1723/4885HPGD 2312/4885
US-20080021060-A1 Quinuclidine carbamate derivatives and their use as M3 antagonists CHRM3, CHRM2, CHRM1 L3MBTL1 2683/4885ALDH1A1 1193/4885HPGD 4155/4885
US-20040242629-A1 Quinuclidine carbamate derivatives and their use as M3 antagonists CHRM3, CHRM2, CHRM1 L3MBTL1 2808/4885ALDH1A1 1591/4885HPGD 4085/4885
US-20040266816-A1 Quinuclidine carbamate derivatives and their use as M3 antagonists CHRM3, CHRM1, CHRM2 L3MBTL1 2461/4885ALDH1A1 1413/4885HPGD 4127/4885
US-20100249420-A9 Process for preparing quinuclidinium carbamate derivatives CPS1, NAAA, QPCT L3MBTL1 4617/4885ALDH1A1 1137/4885HPGD 2071/4885
US-20090054480-A1 NOVEL QUINUCLIDINE CARBAMATE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME CHRM3, CHRM2, CHRM1 L3MBTL1 4397/4885ALDH1A1 2119/4885HPGD 2262/4885
US-20090198064-A1 Process for preparing quinuclidinium carbamate derivatives CPS1, NAAA, QPCT L3MBTL1 4617/4885ALDH1A1 1137/4885HPGD 2071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.